# Immunogenicity and Safety of a Vaccine Against Influenza (2010-2011 Northern Hemisphere Season, Intradermal Route)

> **NCT01138397** · PHASE3 · COMPLETED · sponsor: **Sanofi Pasteur, a Sanofi Company** · enrollment: 129 (actual)

## Conditions studied

- Influenza

## Interventions

- **BIOLOGICAL:** Influenza virus vaccine (split virion, inactivated)
- **BIOLOGICAL:** Influenza virus vaccine (split virion, inactivated)

## Key facts

- **NCT ID:** NCT01138397
- **Lead sponsor:** Sanofi Pasteur, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-06
- **Primary completion:** 2010-07
- **Final completion:** 2010-07
- **Target enrollment:** 129 (ACTUAL)
- **Last updated:** 2015-10-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01138397

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01138397, "Immunogenicity and Safety of a Vaccine Against Influenza (2010-2011 Northern Hemisphere Season, Intradermal Route)". Retrieved via AI Analytics 2026-06-07 from https://api.ai-analytics.org/clinical/NCT01138397. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*